How killer cells take out tumors

The promising drug is known as F8-TNF. When injected into the bloodstream, it lures killer cells from the body's immune system towards sarcomas. The killer cells then destroy the tumours. Researchers from ETH Zurich, led by Professor Dario Neri at the Institute of Pharmaceutical Sciences, developed F8-TNF four years ago. Since then, they have been able to show that it can completely cure sarcomas in mice when combined with a chemotherapeutic agent. Such an effective treatment cannot be achieved by chemotherapy alone or with other therapeutic approaches. Now, a drug closely related to F8-TNF is being tested as part of clinical trials in humans.

Consisting of two sub-units, the F8-TNF molecule works rather like a store detective: just as a detective tracks down a shoplifter and detains it until the police arrive, the molecule identifies cancer cells using its F8 sub-unit and then uses its TNF part to lure killer cells (cytotoxic T cells). TNF is an immune system messenger.

Implanted into the genome
Much of the molecule's mechanism of action was hitherto unclear, but the scientists in Neri's group have now succeeded in working it out. They wanted to find out how the killer cells recognise the tumour after they are lured to it. Although the messenger TNF alerts the killer cells to the tumour's presence, it does not provide them with a specific tumour identifier.

The scientists discovered that the killer cells called by F8-TNF are guided by proteins from specific dormant viruses (endogenous retroviruses). The genetic blueprint of these viruses has implanted itself into the mouse genome during evolution. In many cancer cells, the viral proteins are brought to life. Fragments of these retroviral proteins on the surface of tumour cells allow the killer cells to distinguish cancer cells from healthy cells.

Immune protection against cancer
In addition, the scientists observed that mice where the sarcomas were cured with F8-TNF rejected tissue later transplanted from various types of tumour. "The mice appeared to have acquired a sort of immune protection against cancer. As it turned out, this protection is also due to the killer cells, which recognise the tumour cells with the help of dormant viral proteins," says Philipp Probst, a doctoral student in Neri's group.

In cancer immunotherapy, the body's immune system is activated in order to combat tumours. In the past, many scientists assumed that the killer cells used modified proteins on the surface of tumour cells as an identifier and a point of attack. Tumours are a degenerate form of body tissue; they are formed as a result of certain genetic mutations in a precursor cell, which can lead to protein modifications. "In some cases, mutated proteins can indeed be the distinguishing criterion," says Neri. "In our paper, however, we confirm that killer cells can also use other distinguishing criteria, namely the presence or absence of retroviral proteins."

Aid to understanding
"Now we cannot only cure sarcomas in mice, but also know the mechanism behind this therapy," says Probst. In the relatively new field of cancer immunotherapy, it is important to understand the underlying mechanisms in order to predict which patients will respond best to which therapy.

Further research will be needed to find out whether the observations in mice also apply to humans, as the human genome is full of gene sequences from dormant viruses. In any case, the knowledge may be useful in the interpretation of clinical trials. The third and final phase clinical trials in humans for the active agent L19-TNF, which is related to F8-TNF, will soon begin in Germany; in the US, applications for such trials are currently being examined by the authorities.

More than 100 years ago, New York-based doctor William Coley had already observed that some sarcoma patients recovered spontaneously. These were all patients suffering not only from cancer but also from a bacterial infection. Coley attempted to convert his observation into a therapeutic approach and began to inject sarcoma patients with a cocktail of heat-inactivated bacteria. His experiments were successful and "Coley's toxin" became the therapy of choice for sarcoma patients in the early decades of the 20th century. Although it was later displaced to some extent by radiotherapy and the emerging field of chemotherapy, "Coley's toxin" was still manufactured in Germany until 1990.

In Coley's time, knowledge was not yet advanced enough to understand his cocktail's mechanism of action. From today's perspective, one must assume that the inactivated bacteria triggered an immune response and thus the formation of the messenger TNF. In turn, this messenger activated killer cells that fought the tumour.

Probst P, Kopp J, Oxenius A, Colombo MP, Ritz D, Fugmann T, Neri D.
Sarcoma eradication by doxorubicin and targeted TNF relies upon CD8+ T cell recognition of a retroviral antigen.
Cancer Res. 2017 May 8. pii: canres.2946.2016. doi: 10.1158/0008-5472.CAN-16-2946.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...